ClearPoint Neuro, Inc. (NASDAQ:CLPT) Short Interest Update

ClearPoint Neuro, Inc. (NASDAQ:CLPT) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totalling 712,200 shares, an increase of 15.1% from the September 30th total of 618,500 shares. Based on an average daily trading volume, of 199,200 shares, the short-interest ratio is currently 3.6 days.

ClearPoint Neuro Trading Down 1.2 %

Shares of CLPT opened at $12.86 on Thursday. The firm has a market cap of $354.88 million, a PE ratio of -18.11 and a beta of 1.10. ClearPoint Neuro has a 1-year low of $4.05 and a 1-year high of $14.13. The firm has a fifty day simple moving average of $12.09 and a two-hundred day simple moving average of $8.46.

ClearPoint Neuro (NASDAQ:CLPT) last posted its earnings results on Wednesday, August 7th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. The company had revenue of $7.86 million for the quarter, compared to the consensus estimate of $7.50 million. ClearPoint Neuro had a negative return on equity of 64.23% and a negative net margin of 64.06%. During the same quarter in the prior year, the company earned ($0.29) earnings per share. As a group, research analysts forecast that ClearPoint Neuro will post -0.65 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on CLPT. B. Riley began coverage on shares of ClearPoint Neuro in a research report on Thursday, July 25th. They set a “buy” rating and a $10.00 price target for the company. Lake Street Capital lifted their price objective on ClearPoint Neuro from $11.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th.

Institutional Trading of ClearPoint Neuro

Large investors have recently added to or reduced their stakes in the business. Point72 DIFC Ltd purchased a new position in shares of ClearPoint Neuro during the 2nd quarter worth $32,000. XTX Topco Ltd lifted its position in ClearPoint Neuro by 11.6% during the second quarter. XTX Topco Ltd now owns 13,010 shares of the company’s stock valued at $70,000 after purchasing an additional 1,353 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in ClearPoint Neuro by 7.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 24,867 shares of the company’s stock valued at $170,000 after purchasing an additional 1,813 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in ClearPoint Neuro during the second quarter valued at about $175,000. Finally, Russell Investments Group Ltd. increased its position in ClearPoint Neuro by 23,048.0% in the first quarter. Russell Investments Group Ltd. now owns 46,296 shares of the company’s stock worth $315,000 after buying an additional 46,096 shares in the last quarter. 30.08% of the stock is currently owned by institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.